DFG Collaborative Research Centers
Collaborative Research Centers (CRCs) are joint projects funded by the German Research Foundation (DFG - Deutsche Forschungsgemeinschaft) in which scientists collaborate across disciplines and universities in scientifically excellent research programs.
The CTH is involved in the following CRCs:
CRC 1292
The CRC 1292 is in its 2nd funding period and investigates the causes of inefficient immune responses in tumors and chronic infections with the aim to develop new immunotherapeutic therapies.
Research groups of the CTH are involved in the following subprojects:
- TP02: TF-PAR2 signaling pathway in viral infections (Prof. Wolfram Ruf)
- TP08: Modulation of macrophages and platelets in hepatocellular carcinoma and infection (Jun.-Prof. Carsten Deppermann)
- TP10: Coagulation system-dependent signaling as a regulator of anti-tumor immunity (PD Dr. Claudine Graf + Prof. Wolfram Ruf)
Summary CRC 1292:
- Title: Targeting converging mechanisms of inefficient immunity in tumor diseases and chronic infections
- Spokesperson: Prof. Dr. Hansjörg Schild, University Medicine of the Johannes Gutenberg-University Mainz
- Cooperation partners: Charité Berlin, Georg-Speyer-Haus Frankfurt, Helmholtz Institute for Translational Oncology Mainz, Paul-Ehrlich-Institut Langen, Technical University Dresden, TRON - Translational Oncology gGmbH, University Hospital Frankfurt, University Hospital Cologne
- Funding periods: 2018-2021, 2022-2025
- Further information: CRC 1291
CRC / Transregio 156
The CRC / Transregio 156 is in its 3rd funding period and investigates the role of the skin in defending pathogens, in dealing with environmental triggers and in coordinating systemic immune responses. The goal of the research alliance is to develop novel therapies for chronic inflammatory diseases such as psoriasis.
Research groups of the CTH are involved in the following subprojects:
- C07: PAR2 signaling in cutaneous inflammation (Prof. Wolfram Ruf)
- C08: Resolving the mechanisms of the skin-vasculature-crosstalk in psoriasis-associated vascular dysfunction (PD Dr. Susanne Karbach)
Summary SFB / Transregio 156:
- Titel: The Skin as Sensor and Effector Organ Orchestrating Local and Systemic Immune Responses
- Spokesman: Prof. Dr. med. Alexander Enk, Universitätsklinikum Heidelberg
- Partners: Charité Berlin, Eberhard Karls University Tübingen, LMU Munich, RWTH Aachen University, University Medicine Mainz, Westfälische Wilhelms University Münster
- Funding periods: 2015-2018, 2019-2022, 2023-2026
- Further Informationen: SFB / Transregio 156
CRC / Transregio 355
The CRC / Transregio 355 investigates how regulatory T (Treg) cells influence immunological and tissue-specific diseases. Based on this, customized immunotherapies can be developed in the future with the help of Treg cells.
The research group of Prof. Wolfram Ruf (CTH) is involved in the following subproject:
- A10: Myeloid cell-regulatory T cell crosstalk in thrombus development and resolution
Summary SFB / Transregio 355:
- Titel: Heterogeneity and functional specialization of regulatory T cells in different microenvironments
- Spokesman: Prof. Dr. Ari Waisman, University Medicine of the Johannes Gutenberg-University Mainz
- Partners: LMU Munich, TU Munich
- Funding period: 2023-2026
- Further informationen: SFB / Transregio 355